Wirtek has increased its share capital in connection with the completion of the purchase of the Moltsen Intelligent Software TheCure™ assets. The share capital increase of a nominal value of DKK 39,682 is carried out in reference to the company’s Articles of Association article 3 (9). The nominal value of the share capital now amounts to DKK 2,980,985.00.
The acquisition of the Moltsen Intelligent Software TheCure™ assets is part of Wirtek’s extensive growth and internationalization strategy. The acquisition was carried out February 13, 2007, and after completion of ”Due Diligence” the acquisition is now final.
TheCure™ has subsequently been successfully implemented in the Wirtek organization, and the management expects that the product will ensure Wirtek positive contribution margin both in the short and long term.
TheCure™ is an advanced diagnostic program to be used in the international telecommunication sector ensuring automated troubleshooting processes in mobile networks. By means of “artificial intelligence” errors are not only discovered, but also a precise diagnose is made facilitating the support of networks. Market leading mobile operators in France and Spain, respectively, France Telecom and Telefonica have actively partaken in the development of TheCure™.
For more information:
Michael Aaen, Administrerende direktør, WirTek A/S, Tlf.: +45 7214 6660 – Nibevej 54, 9200 Aalborg SV
Per Vestergaard, Godkendt Rådgiver, CDI Brocorfi A/S, Tlf.: +45 9811 0055
Wirtek A/S is a Danish consultancy services company with strong competences in outsourcing of software development product testing services. We provide our customers with flexible services of high quality at competitive prices from our Development and Test Center in Romania. Our competencies include web-based solutions and portals, mobile solutions as well as embedded systems. Wirtek focuses on building long-term customer partnerships and a win-win relation that creates added value for our customers.